E

Excision BioTherapeutics

48 employees

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Health Care
Therapeutics

Date founded

2015

Funding rounds raised

Total raised

$60M

from 24 investors over 24 rounds

E

Excision BioTherapeutics raised $60M on February 17, 2021

Investors: Cota Capital, ARTIS Ventures, Indusage Partners, Norwest Venture Partners, Anzu Partners, WRVI Capital, Adjuvant Capital, GreatPoint Ventures and Olive Tree Capital

E

Excision BioTherapeutics raised undisclosed on February 2, 2021

Investors: Norwest Venture Partners, ARCH Venture Partners, GreatPoint Ventures, Bossa Nova Investimentos, Redmile Group, Madrona Venture Group, Olive Tree Capital, ARTIS Ventures, Cota Capital and WRVI Capital

E

Excision BioTherapeutics raised undisclosed on March 20, 2020

Investors: Bioverge

E

Excision BioTherapeutics raised $750K on December 20, 2019

Investors: Alumni Ventures Group and Sand Hill Angels

E

Excision BioTherapeutics raised $10M on September 6, 2017

Investors: Oakhouse Partners and ARTIS Ventures

FAQ